Stem Cell Reports ( IF 5.9 ) Pub Date : 2021-08-10 , DOI: 10.1016/j.stemcr.2021.07.009 Rachel Steeg 1 , Sabine C Mueller 2 , Nancy Mah 2 , Bjørn Holst 3 , Alfredo Cabrera-Socorro 4 , Glyn N Stacey 5 , Paul A De Sousa 6 , Aidan Courtney 7 , Heiko Zimmermann 8
Disease-relevant human induced pluripotent stem cells (iPSCs) are generated worldwide for research purposes; however, without robust and practical ethical, legal, and quality standards, there is a high risk that their true potential will not be realized. Best practices for tissue procurement, iPSC reprogramming, day-to-day cultivation, quality control, and data management aligned with an ethical and legal framework must be included into daily operations to ensure their promise is maximized. Here we discuss key learning experiences from 7 years of operating the European Bank for induced Pluripotent Stem Cells (EBiSC) and recommend how to incorporate solutions into a daily management framework.
中文翻译:
EBiSC 最佳实践:如何确保 iPSC 生产线的最佳生成、鉴定和分配
与疾病相关的人类诱导多能干细胞 (iPSC) 在世界范围内产生用于研究目的;然而,如果没有健全和实用的道德、法律和质量标准,它们的真正潜力很可能无法实现。组织采购、iPSC 重新编程、日常培养、质量控制和符合道德和法律框架的数据管理的最佳实践必须纳入日常运营,以确保最大限度地发挥其承诺。在这里,我们讨论了欧洲诱导多能干细胞银行 (EBiSC) 运营 7 年的主要学习经验,并推荐了如何将解决方案纳入日常管理框架。